MedGene Therapeutics is focused on developing ACT treatments (PMBC derived tumor-reactive T cells-Natural Unmodified CD8+ lymphocytes) for two cancers—MSTS (metastatic soft tissue sarcoma) and MFTC (metastatic follicular thyroid cancer)—using NIH patented technology with Worldwide Exclusive License Agreement of commercialization.

Biotechnology

Health Care

Health Diagnostics

MedGene Therapeutics, Inc.

MedGene Therapeutics, Inc.'s headquarters in Silver Spring, MD, United States

Yong H. Park

Robin E. Fontenot

Steve Yoo

Yong W. Moon

Young Jae Ryu

James Song

Rho H. Seong

Eu Chang Hwang

Description

People (1)

Yong H. Park

Jobs